Light Mode
$8.65 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.65, $0.19 below the day’s high of $8.84
+2.43 (+39.07%) / 6M
Momentum, market sentiment, and recent alerts
QTTB reads neutral: price sits above one of the two key moving averages, the 12-month move is +191.2%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.